Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus chemotherapy as neoadjuvant therapy for stage II-IIIB squamous non-small cell lung cancer
ChiCTR2500104283Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in Pulmonary squamous cell carcinoma, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Pathologic complete response rate (pCR). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2500104283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104283.